Genetic background influences cardiac phenotype in murine chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 33, Issue 7, 2018, Pages 1129-1137

  Neuburg, Samantha ^a   Dussold, Corey ^a   Gerber, Claire ^a   Wang, Xueyan ^a   Francis, Connor ^a   Qi, Lixin ^a   David, Valentin ^a   Wolf, Myles ^b   Martin, Aline ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Chronic kidney disease; Col4a3 null mouse; FGF23; genetic background; left ventricular hypertrophy

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MESSENGER RNA; MYOSIN HEAVY CHAIN BETA; NITROGEN; UREA; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; FGF23 GENE; FGFR4 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC BACKGROUND; GENETIC RISK; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART STROKE VOLUME; HIGH RISK PATIENT; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LIFESPAN; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; UREA NITROGEN BLOOD LEVEL; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE EXACERBATION; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BIOMARKERS; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RENAL INSUFFICIENCY, CHRONIC; RNA;

EID: 85048729887     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfx332     Document Type: Article

References (41)

1. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl JMed 2008; 359: 584-592
2. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
3. Isakova T, Houston J, Santacruz L et al. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediatr Nephrol 2013; 28: 2035-2042
4. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22: 956-966
5. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
6. Grabner A, Amaral AP, Schramm K et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015; 22: 1020-1032
7. Hu MC, Shi M, Cho HJ et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol 2015; 26: 1290-1302
8. Di Marco GS, Reuter S, Kentrup D et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant 2014; 29: 2028-2035
9. Zou H, Zhao X, Sun N et al. Effect of chronic kidney disease on the healing of titanium implants. Bone 2013; 56: 410-415
10. Hofman-Bang J, Martuseviciene G, Santini MA et al. Increased parathyroid expression of klotho in uremic rats. Kidney Int 2010; 78: 1119-1127
11. Ferrari GO, Ferreira JC, Cavallari RT et al. Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models. BMC Nephrol 2014; 15: 69
12. Jia T, Olauson H, Lindberg K et al. A novel model of adenine-induced tubulointerstitial nephropathy inmice. BMC Nephrol 2013; 14: 116
13. Rabe M, Schaefer F. Non-transgenic mouse models of kidney disease. Nephron 2016; 133: 53-61
14. Qiao JH, Xie PZ, Fishbein MC et al. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb 1994; 14: 1480-1497
15. Lemmink HH, Schroder CH, Monnens LA et al. The clinical spectrum of type IV collagenmutations. HumMutat 1997; 9: 477-499
16. Cosgrove D, Kalluri R, Miner JH et al. Choosing a mouse model to study the molecular pathobiology of Alport glomerulonephritis. Kidney Int 2007; 71: 615-618
17. Kang JS, Wang XP, Miner JH et al. Loss of alpha3/alpha4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to alpha5alpha6(IV) collagen associated with longer renal survival in Col4a3-/-Alportmice. J Am Soc Nephrol 2006; 17: 1962-1969
18. Stubbs JR, He N, Idiculla A et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J BoneMiner Res 2012; 27: 38-46
19. Dai B, David V, Alshayeb HMet al. Assessment of 24, 25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int 2012; 82: 1061-1070
20. Touchberry CD, Green TM, Tchikrizov V et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol EndocrinolMetab 2013; 304: E863-E873
21. Dai B, David V, Martin A et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One 2012; 7: e44161
22. David V, Martin A, Isakova T et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 2016; 89: 135-146
23. Andrews KL, Mudd JL, Li C et al. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 2002; 160: 721-730
24. Martin A, David V, Li H et al. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hypmice. Mol Endocrinol 2012; 26: 1883-1895
25. Antignac C. Molecular genetics of basement membranes: the paradigm of Alport syndrome. Kidney Int Suppl 1995; 49: S29-S33
26. Hudson BG, Reeders ST, Tryggvason K et al. Collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 1993; 268: 26033-26036
27. Deltas C, Pierides A, Voskarides K. Molecular genetics of familial hematuric diseases. Nephrol Dial Transplant 2013; 28: 2946-2960
28. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J AmSocNephrol 2010; 21: 1427-1435
29. Christov M, Waikar SS, Pereira RC et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 2013; 84: 776-785
30. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980
31. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 2014; 23: 411-419
32. Farrow EG, Yu X, Summers LJ et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011; 108: E1146-E1155
33. Mariyama M, Leinonen A, Mochizuki T et al. Complete primary structure of the human alpha 3(IV) collagen chain. Coexpression of the alpha3(IV) and alpha4(IV) collagen chains in human tissues. J Biol Chem 1994; 269: 23013-23017
34. Earl TJ, Khan L, Hagau D et al. The spectrum of aortic pathology in alport syndrome: a case report and review of the literature. Am J Kidney Dis 2012; 60: 821-822
35. Bassareo PP, Marras AR, Mercuro G. Ventricular septal defect in a child with Alport syndrome: a case report. BMC Cardiovasc Disord 2010; 10: 48
36. Ferrari F, Nascimento P, Jr, Vianna PT. Complete atrioventricular block during renal transplantation in a patient with Alport's syndrome: case report. Sao PauloMed J 2001; 119: 184-186
37. Sasaki N, Joashi UC, Vergara M et al. Postrenal biopsy AVM leading to severe hypertension and dilated cardiomyopathy. Pediatr Nephrol 2009; 24: 2459-2462
38. Ghosh S, SinghM, Sahoo R et al. Alport syndrome: a rare cause of uraemia. BMJ Case Rep 2014; 2014; bcr2013201731
39. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259
40. Leifheit-Nestler M, Grabner A, Hermann L et al. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats. Nephrol Dial Transplant 2017; 32: 1493-1503
41. Leifheit-Nestler M, Grosse Siemer R, Flasbart K et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant 2016; 31: 1088-1099